Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuropsychiatr Dis Treat. 2008 Apr;4(2):337-52.

Update on the use of pramipexole in the treatment of Parkinson's disease.

Author information

1
Department of Neurology, Sahlgrenska University Hospital 413 45 Göteborg, Sweden. radu.constantinescu@vgregion.se

Abstract

Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson's disease (PD). This review addresses the literature concerning pramipexole's efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.

KEYWORDS:

Parkinson’s disease; adverse events; efficacy; pramipexole

PMID:
18728740
PMCID:
PMC2518382
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center